alexa Induced Pluripotent Stem Cells for the Treatment of Hem
ISSN: 2157-7013

Journal of Cell Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Induced Pluripotent Stem Cells for the Treatment of Hemophilia A

Bilgimol C Joseph and Manjunath S Rao*

Micro Therapeutic Research Labs Pvt Ltd, Chennai, Tamilnadu, India

*Corresponding Author:
Manjunath S Rao
No: 6, 'Rajam Bhavanam, Kamarajar Salai
East Tambaram, Selaiyur, Chennai - 600 059, India
Tel: +91 44 2239 0070 / 71 / 72
Fax: +91 44 2239 0068
E-mail: [email protected]

Received date: November 01, 2014; Accepted date: November 03, 2014; Published date: November 04, 2014

Citation: Joseph BC, Rao MS (2014) Induced Pluripotent Stem Cells for the Treatment of Hemophilia A. J Cell Sci Ther 5:e119. doi: 10.4172/2157-7013.1000e119

Copyright: © 2014 Joseph BC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Factor VIII, one of the most complex proteins known, plays a major role in blood coagulation pathway. Defects in factor VIII protein result in hemophilia A, a severe bleeding disorder. Plasma derived factor VIII or recombinant factor VIII has been used extensively for treating hemophilia A patients. Number of attempts at gene therapy for hemophilia A has failed for various unknown/not much studied reasons including immune rejection. Here, the progress that has been made in establishing iPSC-based disease models and the potentials of iPSC technology for personalized medicine and cell therapy for hemophilia A are reviewed. The challenges of iPSC technology are also briefly discussed.

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version